Ion-827359

Author: wxuy

August undefined, 2024

WebA Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple … Web20 apr. 2024 · ION-827359 is a 2·5-generation antisense oligonucleotide drug targeted to reduce the ENaC protein. This study evaluated the safety, pharmacokinetics (PK), and …

Safety and Tolerability Demonstrated with Inhaled αENaC …

WebThis is a multi-center, double-blind, placebo-controlled, randomized, Phase 2a study of ION-827359 in up to 180 participants. The participants will be randomized to receive oral … first pass metabolism is avoided by

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of …

WebA Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Patients with Mild to Moderate COPD with Chronic Bronchitis: … Web18 jun. 2024 · The purpose of this study was to evaluate the effect of ION-827359 on forced expiratory volume in 1 second (FEV1) in participants with mild to moderate COPD with … Web3 aug. 2024 · Safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ION-827359, an antisense oligonucleotide inhibitor of ENaC, in healthy … first pass mini

Antisense Pipeline Ionis - Ionis Pharmaceuticals, Inc.

Covid 19 Clinical Trials

Web[VIRTUAL] Safety and Tolerability Demonstrated with Inhaled αENaC Antisense Oligonucleotide (ION-827359) in Patients with Cystic Fibrosis (ATS 2024) - "These … WebA Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis … first pass metabolism of a drug explainsWebA Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple … first pass perfusion cmr

"Web29 mrt. 2024 · We Are Transforming the Standard of Care and Pioneering New Markets As the leader in RNA-targeted therapeutics for more than three decades, Ionis has focused … " - Ion-827359

Ion-827359

Web23 dec. 2024 · ION-827359 from Ionis is an inhalable Gapmer ASO formulation being developed for CF to assess the hyperactivity of ENaCs, though this trial has been paused due to safety concerns. The ASO sequence has the (S)-cEt modification that provides excellent target affinity and nuclease resistance. WebResults: ION-827359 was well-tolerated with an acceptable safety profile after multiple inhalations. The rate of adverse events was similar between ION-827359 and placebo …

Did you know?

WebION-827359 SODIUM Code; ION-827359, SODIATED FORM Code; UNII Resources. Common Chemistry CAS Common Chemistry is an open community resource of the American Chemical Society for accessing chemical information. WebCreated by admin on Fri Jun 25 20:50:30 UTC 2024, Edited by admin on Fri Jun 25 20:50:30 UTC 2024

WebION-827359 is a chemically modified ASO, 16 nucleotides in length with a phosphorothioate backbone and constrained ethyl (cEt) modifications. In healthy volunteers the ASO was … Web11 mei 2024 · ion-827359. Showing 1 - 1 of 1. Trials per page: STUDY. CONDITIONS. INTERVENTIONS. LOCATIONS. LAST UPDATED Chronic Bronchitis, COPD Trial in …

WebThe hypothesis of using an epithelial sodium channel (ENaC) blocking molecule to restore ASL has been studied in pre-clinical and clinical studies. The study drug in this study is … WebFull Analysis Set (FAS) included all randomised subjects who received at least 1 dose of study drug (ION‑827359 or placebo) and who had at least 1 post-Baseline efficacy …

WebION-827359 SODIUM Code; ION-827359, SODIATED FORM Code; UNII Resources. Common Chemistry CAS Common Chemistry is an open community resource of the …

Web27 aug. 2024 · A Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and … first pass metabolism pharmacologyWebION-827359 : D.3.4: Pharmaceutical form : Inhalation solution: D.3.4.1: Specific paediatric formulation: No : D.3.7: Routes of administration for this IMP: Inhalation use: D.3.8 to … first-pass myocardial ct perfusionWeb22 jun. 2024 · Drug: ION-827359 Drug: Placebo. Phase 2. Detailed Description: This was a multi-center, double-blind, placebo-controlled, randomized, Phase 2a study of ION … first-pass metabolism in the liverWebBackground and objective: Atacicept is an inhibitor of the B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), and is being studied in relation to … first passport after naturalisation timelineWebSchneider Electric Global. Browse our products and documents for PowerLogic ION7300 series - Highly-configurable meters for feeders or critical loads first passport after naturalisation ukWebA Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Patients with Mild to Moderate COPD with Chronic Bronchitis: … first passport application childWeb4 jul. 2024 · Cofirasersen - Ionis Pharmaceuticals - AdisInsight Drug Profile Cofirasersen - Ionis Pharmaceuticals Alternative Names: ENaC ASO - Ionis Pharmaceuticals; … first passover in the bible